Eluminex Biosciences has dosed the first patient in the phase 1b LOTUS trial, which will evaluate three dose levels of the trispecific fusion antibody EB-105 in patients with diabetic macular edema.
“It is our hope that EB-105 will translate into incremental improvements in visual acuity, durability of response and improved drying of the retina,” Ashkan Abbey, MD, director of clinical research at Texas Retinal Associates and the first retinal surgeon to administer the treatment, said in an Eluminex press release.
As Healio recently reported, EB-105 has three major moieties that